David Shprecher, DO
Neurology · Sun City, AZNPI 1679692594
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $130,613 of the $193,418 with a category attached, or 67.5%. 33 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 36.6% of the total. Reporting peaked in 2019 at $83,983 and has fallen 96.8% since, to $2,725 in 2025. Among neurology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 547 payments — averaging $353.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$71K
- Teva Pharmaceuticals USA, Inc.$47K
- Acorda Therapeutics, Inc$27K
- Amneal Pharmaceuticals LLC$14K
- MDD US Operations, LLC$12K
- Sunovion Pharmaceuticals Inc.$6K
- plus $15K from 27 others
Across 119 payments — averaging $6021.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$267K
- Biogen$174K
- Eisai Inc.$89K
- Sanofi$70K
- AbbVie$62K
- Neurocrine Biosciences, Inc.$35K
- plus $19K from 1 others
What the payments were for
- Consulting fees$34,16718%
- Speaking & faculty fees$130,61368%
- Travel & lodging$13,0907%
- Food & beverage$15,2468%
- Education$3030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 127 | $70,848 |
| Teva Pharmaceuticals USA, Inc. | 63 | $47,257 |
| Acorda Therapeutics, Inc | 50 | $27,066 |
| Amneal Pharmaceuticals LLC | 43 | $14,424 |
| MDD US Operations, LLC | 55 | $12,431 |
| Sunovion Pharmaceuticals Inc. | 11 | $6,010 |
| Kyowa Kirin, Inc. | 7 | $3,418 |
| AbbVie(2 entities) | 49 | $3,236 |
| Jazz Pharmaceuticals Inc. | 10 | $1,628 |
| Biogen | 16 | $1,545 |
| Acadia Pharmaceuticals Inc | 44 | $1,159 |
| UCB SA | 2 | $1,100 |
| Ipsen Biopharmaceuticals, Inc | 10 | $975 |
| Merz Pharmaceuticals, LLC | 14 | $560 |
| UCB, Inc. | 12 | $507 |
| Medtronic(2 entities) | 7 | $484 |
| Supernus Pharmaceuticals, Inc. | 2 | $127 |
| Tanabe Pharma America, Inc. | 1 | $100 |
| Axsome Therapeutics, Inc. | 1 | $76 |
| Adamas Pharmaceuticals, Inc. | 4 | $74 |
| Revance Therapeutics, Inc. | 1 | $68 |
| Merz North America, Inc. | 2 | $52 |
| Vertical Pharmaceuticals, LLC | 3 | $48 |
| Arbor Pharmaceuticals, Inc. | 3 | $48 |
| Cala Health, Inc. | 2 | $46 |
| Eisai Inc. | 1 | $27 |
| Lundbeck LLC | 1 | $23 |
| Avion Pharmaceuticals | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Azurity Pharmaceuticals, Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$193,418 in reported general payments places this provider in the 90th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 84 | $731,569 |
| AustedoDeutetrabenazine | 49 | $396,039 |
| NuplazidPimavanserin Tartrate | 66 | $339,432 |
| RytaryCarbidopa/Levodopa | 220 | $204,050 |
| Droxidopa | 81 | $167,386 |
| GocovriAmantadine Hcl | 51 | $162,710 |
| InbrijaLevodopa | 14 | $29,635 |
| NourianzIstradefylline | 14 | $25,710 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 486 | $21,628 |
| Rasagiline Mesylate | 91 | $19,962 |
| HorizantGabapentin Enacarbil | 16 | $19,404 |
| LinzessLinaclotide | 27 | $17,468 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 228 | $16,813 |
| AmantadineAmantadine Hcl | 114 | $10,007 |
| Pramipexole ErPramipexole Di-Hcl | 15 | $9,639 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $70,848 | $731,56984 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $47,257 | $396,03949 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,159 | $339,43266 claims |
| Amneal Pharmaceuticals LLCRytary, Crexont, Pyridostigmine Bromide | $14,424 | $214,131272 claims |
| MDD US Operations, LLCGocovri | $12,431 | $162,71051 claims |
| Acorda Therapeutics, IncInbrija | $27,066 | $29,63514 claims |
| Kyowa Kirin, Inc.Nourianz | $3,418 | $25,71014 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $48 | $19,40416 claims |
| AbbVieLinzess | $3,236 | $17,46827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 neurology providers in Arizona.
Other neurology in Sun City
- Holly LaubSun City$39K
- Mona MehtaSun City$33K
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Nida LaurinScottsdale$969K
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
- Kerry KnievelPhoenix$509K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.